Search
Invitrogen
CD16/CD30 Humanized (Bi-specific) Recombinant Human Monoclonal Antibody (AFM13)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Additional Information:
{{banner.description}}
Product Details
MA562424
Applications
Tested Dilution
Publications
Product Specifications
Species Reactivity
Human
Host/Isotype
Human
/ VH-VL-VH-VL
Expression System
CHO cells
Class
Recombinant Monoclonal
Type
Antibody
Clone
AFM13
Conjugate
Unconjugated
Unconjugated
Unconjugated
Form
Liquid
Concentration
0.87 mg/mL
Amount
100 µg
Purification
Protein A/G
Storage buffer
PBS, pH 7.4
Contains
no preservative
Storage conditions
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Shipping conditions
Ambient (domestic); Wet ice (international)
RRID
Target Information
CD16 and CD30 are important targets in immunotherapy particularly for the treatment of various cancers. CD16 also known as Fc gamma receptor III is primarily expressed on natural killer (NK) cells and macrophages and is involved in antibody-dependent cellular cytotoxicity (ADCC) wherein effector cells recognize antibody-coated target cells. Biosimilars targeting CD16 are utilized to enhance the efficacy of therapeutic antibodies by optimizing interactions with NK cells. Polymorphisms in CD16 could influence the effectiveness of these therapies as seen in studies evaluating different CD16 variants. CD30 on the other side is predominantly expressed in lymphoma cells such as Hodgkin lymphoma and anaplastic large cell lymphoma making it a significant target for antibody-drug conjugates (ADCs) and CAR-T cell therapies. Anti-CD30 therapies utilize monoclonal antibodies or engineered T cells to specifically target and destroy CD30-expressing tumor cells. Research into biosimilars or related compounds such as those utilizing CD30 with CD3 bispecific antibodies seeks to improve specificity and reduce off-target effects leveraging the restricted nature of CD30 expression in healthy tissues. This highlights the therapeutic potential and advancements in the use of biosimilars targeting CD16 and CD30 in oncology.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
References (0)
Have you cited this product in a publication?
Let us know so we can reference it here.
Bioinformatics
Protein Aliases: CD16-II; CD16a; CD16a antigen; CD30; CD30L receptor; Fc gamma receptor III; Fc-gamma RIII; Fc-gamma RIII-alpha; FcR-10; IgG Fc receptor III-2; IgG Fc receptor III-A; Ki-1; Ki-1 antigen; Low affinity immunoglobulin gamma Fc region receptor III-A; Lymphocyte activation antigen CD30; lymphocyte antigen; Tumor necrosis factor receptor superfamily member 8
Gene Aliases: CD16A; CD30; D1S166E; FCG3; FCGR3; FCGR3A; IGFR3; TNFRSF8
Entrez Gene ID: (Human) 2214, (Human) 943
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Performance Guarantee
If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*
Learn more
We're here to help
Get expert recommendations for common problems or connect directly with an on staff expert for technical assistance related to applications, equipment and general product use.
Contact tech support